AXIM BIOTECHNOLOGIES INC - AXIM STOCK NEWS

AXIM has optimized its R&D and manufacturing for diagnostic solutions and expects to achieve cash-flow positivity by mid-2023. The company continues to generate revenue through its FDA-cleared dry eye disease tests, in partnership with Verséa Ophthalmics. AXIM is focusing on developing custom diagnostics and aims to file for a CLIA waiver for its tests early this year, potentially expanding its market. A clinical study for its MMP-9 test is also in the pipeline. A conference call with investors is scheduled for January 11, 2023.

AXIM Biotechnologies announced the filing of a provisional patent for a rapid ophthalmological diagnostic solution that measures both Ocular Immunoglobulin E (IgE) and MMP-9. This innovative test requires only a 2-microliter sample, reducing patient discomfort and providing quantitative results in 10 minutes. The test aims to improve the diagnosis and treatment of Dry Eye Disease and other common eye conditions. The company anticipates advancing clinical development in early 2023, with potential FDA approval adding to its portfolio of diagnostic tools for clinicians.

AXIM Biotechnologies announced its tear-based diagnostic solutions for ocular surface disease were highlighted in major media outlets including Eyes On 2023 and Ophthalmology Times. Interviews with Dr. Rob Sambursky from Verséa Ophthalmics discussed the benefits of these innovative tests, including the Lactoferrin test, which allows clinicians to make rapid treatment decisions based on real-time data. AXIM is also developing additional tests aimed at enhancing patient care. The company continues to collaborate with Verséa to commercialize these FDA-cleared solutions.

AXIM Biotechnologies announced a significant milestone by securing an initial order of 19,000 point-of-care diagnostic tests and 100 digital readers from Verséa Ophthalmics, marking the company's first large revenue-generating order. This order will enable the company to provide rapid diagnostic tests for ocular surface diseases, receiving substantial momentum from a commercial launch at the 2022 American Academy of Ophthalmology conference. The tests, which are FDA-cleared, facilitate accurate diagnoses in under 10 minutes, paving the way for improved patient care.

AXIM Biotechnologies has commenced sales of its point-of-care diagnostic tests for ocular surface disease at the American Academy of Ophthalmology Annual Meeting, in partnership with Verséa Ophthalmics. The exclusive partnership aims to promote two FDA-cleared tests that measure tear levels of Lactoferrin and Immunoglobulin E (IgE). These tests allow for rapid diagnosis of conditions like dry eye disease and allergic conjunctivitis, enhancing patient care. The event is held from September 30 to October 3 in Chicago, where Verséa will showcase the products at Booth 1251.

AXIM Biotechnologies has entered an exclusive global commercial partnership with Verséa Ophthalmics to sell and distribute AXIM’s proprietary tests targeting Dry Eye Disease and allergic conjunctivitis. Verséa will utilize its established distribution channels to launch the Ocular IgE and Lactoferrin tests at upcoming conferences, with the MMP-9 test expected within 18-24 months. This agreement marks AXIM's transition from a development stage to a revenue-generating organization, showcasing commitments to enhancing diagnostic solutions for ocular conditions.

SAN DIEGO, July 26, 2022 – AXIM Biotechnologies, Inc. (OTCQB: AXIM) announced the launch of an enhanced rapid Ocular Immunoglobulin E (IgE) test, responding to climate change-driven trends in allergy seasons. A recent study indicates that allergy seasons are becoming longer and starting earlier. AXIM's optimized IgE test offers results 50% faster, aiding the diagnosis of allergic conjunctivitis, affecting 40% of the U.S. population annually. CEO John W. Huemoeller II emphasized the need for improved diagnostic tools to handle the increasing prevalence of ocular allergies as seasons change.

SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. announced a publication with Arizona State University titled, "Third COVID-19 Vaccine Dose Boosts Neutralizing Antibodies in Poor Responders" in Communications Medicine. The study revealed that 25% of vaccine recipients did not achieve adequate neutralizing antibodies after two doses, but a third dose significantly increased these levels within two weeks. AXIM's rapid test, co-developed with ASU, quantitatively measures neutralizing antibodies, underscoring its potential role in personalized medicine.